Adar Poonawalla, CEO of Serum Institute of India and Chairman of Poonawalla Fincorp, has recently acquired a 50% stake in ...

This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...

Monopar Therapeutics shares rose after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion. Shares of the Wilmette, Ill., ...

Executives from AstraZeneca, Kroger and Verizon are adapting workforce strategies to focus on training, building awareness ...

Semaglutide (Ozempic) was tied to a reduced risk of Alzheimer's disease diagnoses in people with type 2 diabetes, ...

Initial OnKure Therapeutics, Inc. data from PIKture-01 study on OKI-219 for PI3Ka-H1047R breast cancer expected in Q4, 2024.

Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. | Monopar Therapeutics ...

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give ...

Monopar’s year-to-date performance is nothing short of phenomenal, boasting a staggering +1190.59% increase. In contrast, the S&P 500 has shown a more modest gain of +21.81%. This dramatic difference ...

Five industries are poised to drive Sydney’s economic future, with new forecasts showing finance, biotech, digital-tech, ...

On CGEN's third-quarter 2024 earnings call, investors' focus is likely to be on updates on its pipeline candidates being studied for cancer immunotherapies.

Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's ...